For illustrative purposes only. Not actual physician.
Confidence for THE LONG TERM
Treatment selection for long-term success
Together, these treatment selection pillars, a framework created by Gilead, highlight considerations that can help people with HIV achieve durable viral suppression and long-term success.
Gilead believes that long-term success means attaining US Department of Health and Human Services (DHHS) treatment goals*,1 for the long term.
*Once initiated, antiretroviral therapy (ART) should be continued with the following key treatment goals, as identified by the DHHS: maximally and durably suppress plasma HIV ribonucleic acid (RNA); restore and preserve Immunologic function; reduce HIV-associated morbidity and prolong the duration and quality of survival; and prevent HIV transmission.1
According to DHHS and the Office of Disease Prevention and Health Promotion (OASH), the social determinants of health (SDOH) are the conditions in the environments where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks. SDOH can be grouped into 5 domains including Economic Stability, Education Access and Quality, Health Care Access and Quality, Neighborhood and Built Environment, and Social and Community Context.2
Explore a comprehensive treatment approach
HIV care that supports long-term success starts with a comprehensive approach to treatment selection.1
Consider these key attributes when selecting a treatment that could help contribute to long-term success:
Person-Centered
Evaluating the dynamic realities of your patients’ lives when considering treatments can help set them up for long-term success.1
High Barrier to Resistance
Resistance mutations may jeopardize future treatment options. Understand the risks.1
Rapid Start
Rapid antiretroviral therapy (ART) initiation should be offered to all patients with HIV immediately after diagnosis or as soon as possible.1
Experience
Rigorously evaluated treatment data with diverse representation may help you make individualized decisions for the different patient groups you see in your practice.1,3
Safety & Tolerability
A safety and tolerability profile that could help support people with HIV through many stages of life.1
ART, antiretroviral therapy; DHHS, US Department of Health and Human Services; OASH, Office of Disease Prevention and Health Promotion; RNA, ribonucleic acid.
References:
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated February 27, 2024. Accessed July 24, 2024. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf
- Healthy People 2030. Social determinants of health. US Department of Health and Human Services. Updated April 6, 2022. Accessed July 29, 2024. https://health.gov/healthypeople/priority-areas/social-determinants-health
- US Food and Drug Administration. Clinical trial diversity. Updated May 8, 2024. Accessed September 12, 2024. https://www.fda.gov/consumers/minority-health-and-health-equity-resources/clinical-trial-diversity